Metabolic syndrome patients have three or more than three of the complications such as hyperglycemia, high blood pressure, abdominal obesity, increased triglycerides and decreased high density lipoprotein levels. People with metabolic syndrome have an increased risk for developing cardiovascular diseases. Renal denervation is a minimally invasive procedure that is being investigated and proposed to treat patients with drug resistant hypertension. Clinical trials of catheter based renal denervation have proved its safety and efficacy in reducing blood pressure. In clinicals trials, renal nerve ablation is reported to have off-target effects such as decrease muscle sympathetic nerve activity, decrease in blood glucose, and decrease arrhythmia, other than its primary goal of reducing blood pressure. This creates curiosity to use renal denervation for treating the people with metabolic syndrome. Previous works in various animal models of high blood pressure show that renal denervation reduces blood pressure by affecting renal inflammation, but their action on glucose metabolism is not well studied. Our main objective using a model of metabolic syndrome- in both male and female mice- is to explore the role of the renal nerve (both sensory afferent and efferent nerves) in blood pressure regulation and glucose metabolism. This study will help understand the molecular mechanism of renal nerve mediated blood pressure control and glucose regulation in normal physiology and complex disease state.